Invivyd Inc (IVVD) News

Form 8-K - Current report

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Independent evaluation of KP.3.1.1 and LB.1 variants shows in vitro pseudovirus neutralization potency of...

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase...

Form 8-K - Current report

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Form 8-K - Current report

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) --  Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Form 8-K - Current report

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart...

Form 8-K - Current report

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report